Unboxing the Australian Government’s $100m patent scheme

Current site :    AU   |   EN
China Hong Kong SAR
United Kingdom
United States

Written by Kim O'Connell, Luke Hawthorne and Shelby Koh

One of the key measures targeting innovation in the Federal budget announced on 11 May 2021, is the introduction of a 'patent box scheme' worth over $100 million annually.  

Will it work to encourage Australian medical and biotechnology innovation?

Patent Box at a glance

  • Applies to medical and biotechnology patents applied for after 11 May 2021 once they are granted
  • Income from eligible patents will be taxed at the concessional corporate tax rate of 17%
  • Takes effect from 1 July 2022
  • Scheme value – budget estimates over $100 million per year

The patent box scheme is aimed at encouraging organisations to research and develop their medical and biotechnology innovations in Australia.  The goal of the scheme is to drive investment in those sectors and to ensure that innovators are filing patents for those innovations in Australia.  

The scheme brings Australia in line with over 20 other countries who have introduced similar schemes, including the UK, France, Singapore and China. It is set to come into effect from July 2022 and will provide a tax concession for income from granted Australian patents that are applied for after 7:30pm on the day of the budget announcement - Tuesday 11 May 2021.

The concession means that corporate income derived from Australian-owned medical and biotech patents will be taxed at a reduced rate of 17%, rather than the usual rates of 30%, or 25% for SMEs.  The concession will only apply to income derived directly due to the patent.  Ancillary income such as that from manufacturing and branding will continue to be taxed at normal corporate rates.

The worked example provided in the Budget fact sheets indicates that the concession may be proportionally applied where only part of the research and development leading to the patent occurs in Australia.

The patent box scheme complements the Federal Government's $2 billion investment in the Research and Development Tax Incentive and its precise operation will be finalised after close consultation with industry on its design.   Together these measures aim to further increase the attractiveness of Australia as a jurisdiction for research and development in the medical and biotechnology sectors.

Theory and Practice: How will it work, who wins and loses?

Patent boxes have been criticised in a number of respects – principally for incentivising filing patents over true innovation and increased economic contribution.  However, a report from the Office of the Chief Economist in 2015[1] found that Australia lagged behind other developed countries in providing incentives for research and development.  It is to be hoped that the introduction of the Australian patent box scheme will further level the playing field for companies choosing a location for research and development.

However, as that Report acknowledged, while "[t]he lower tax rate will ultimately increase post-tax profits of innovative firms…. only a narrow range of innovative firms are likely to benefit from the patent box regime, namely firms that hold patents and conduct R&D"[2].  Particularly in the medical and biotechnology fields, innovators in AI and other forms of technology are likely to be significant therapeutic and economic contributors, but illogically, may not benefit from the patent box's tax incentives.

Nevertheless, if the Australian patent box scheme is well designed and positively received, it could be rolled out to other industries.  The Government has flagged that it plans to next examine whether a patent box is an effective way of supporting developments in clean energy.

How does this compare with competing countries?

The Government has indicated that the scheme will follow the OECD's guidelines on patent boxes to ensure that it meets internationally accepted standards. 

As an example of schemes already in operation, the UK introduced a patent box scheme which was designed to encourage companies to keep and commercialise IP in the UK.  The UK scheme permits companies to 'elect in' to apply a lower rate of corporate tax (10%) to profits earned as a result of patented inventions.  To be eligible to use the patent box scheme, companies must be liable to corporate tax, make a profit from exploiting patented inventions, own or have exclusively licensed-in the patents and have undertaken qualifying development on the invention claimed in the patents.  Satisfying the 'qualifying development' requirement means that companies must create, or significantly contribute to, the creation of the patented invention, or must perform a significant amount of activity to develop the patented invention or to develop any product or process incorporating the patented invention.

Similarly, China's patent box regime allows income from patents and certain types of commercial know-how to qualify for a lower corporate income tax rate. Once a company has reduced its taxes by 5 million RMB (approximately AU$1 million) then further income that qualifies for the patent box is taxed at half the corporate tax rate (currently this equates to 12.5%).

China also provides a lower tax rate to companies that spend at least 3% to 6% (depending on their size)  of their gross revenue on research and development have 60% of revenue from core IP (defined as inventions, utility model patents, software, copyrights, proprietary layout designs, and new plant varieties), and have 30% of their workforce with a college degree or 10% of their workforce employed in research and development or high tech occupations.

Next Steps

Australian companies will have an opportunity to shape the Australian patent box scheme as the Government rolls out a consultation process in the lead up to implementation of its scheme mid next year. 

Please get in touch if you would like to discuss the proposed scheme or if we can assist you in the Government's consultation process.

[1] Patent Box Polices, (2015) p. 1.

[2] Ibid.  p. 14.

On 2 August 2022, the Aged Care and Other Legislation Amendment (Royal Commission Response) Bill 2022 was passed (Aged Care Bill), introducing important regulatory changes to Australia’s aged care sector. The Bill makes numerous legislative amendments, including to the Aged Care Act 1997 (Cth) (Aged Care Act) and the Aged Care (Transitional Provisions) Act 1997 (Cth) (Transitional Provisions Act), and responds to various recommendations made by the Royal Commission into Aged Care Quality and Safety (Royal Commission) Final Report (Report). The Report identified the provision of substandard aged care services and perceived systemic failures in the aged care sector.[1]

08 August 2022

The Federal Court has refused an application to stay proceedings to quantify compensation for patent infringement (quantum proceedings) pending the outcome of separate parallel proceedings challenging the validity of the infringed patent on new grounds. The case is significant as intellectual property cases are regularly bifurcated with liability determined separately damages or an account of profits. A patentee may also bring consecutive infringement cases and therefore have two separate cases considering invalidity issues for the same patent running in parallel.

03 August 2022

Since the introduction of a nationwide Marketing Authorization Holder (MAH) system in 2019, licenses have linked directly to therapeutic products rather than manufacturers.

03 August 2022